NeuBase Therapeutics, Inc. (NBSE) News

NeuBase Therapeutics, Inc. (NBSE): $1.01

-0.04 (-3.81%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add NBSE to Watchlist
Sign Up

Industry: Biotech


Ranked

of 427

in industry

Filter NBSE News Items

NBSE News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

NBSE News Highlights

  • NBSE's 30 day story count now stands at 2.
  • Over the past 10 days, the trend for NBSE's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about NBSE are DRUG and PK.

Latest NBSE News From Around the Web

Below are the latest news stories about NeuBase Therapeutics Inc that investors may wish to consider to help them evaluate NBSE as an investment opportunity.

NeuBase Therapeutics Reports Business Update and Financial Results for the First Quarter of Fiscal Year 2022

Investigational New Drug (IND)-enabling studies for the myotonic dystrophy type 1 (DM1) program development candidate continue as planned; invited to present new rodent pharmacokinetic (PK) and bioavailability data in an oral presentation at an upcoming scientific meeting; expects to submit an IND application to the U.S. Food and Drug Administration (FDA) in the fourth quarter (Q4) of calendar year (CY) 2022Good Manufacturing Practice (GMP) manufacturing to support Phase 1/2 clinical trials for

Yahoo | February 11, 2022

Is NeuBase Therapeutics (NASDAQ:NBSE) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Yahoo | February 1, 2022

NeuBase Therapeutics hires new chief financial officer

NeuBase Therapeutics, a Pittsburgh-based developer of genetic medicines, announced that it has hired Todd Branning as its new chief financial officer.

Yahoo | January 11, 2022

NeuBase Therapeutics names Phathom''s Todd Branning as new CFO

NeuBase Therapeutics (NBSE) appoints Todd P. Branning as the company''s new chief financial officer. Prior to joining NeuBase, Branning served as CFO of Phathom Pharmaceuticals (PHAT)…

Seeking Alpha | January 10, 2022

NeuBase Therapeutics Appoints Todd P. Branning Chief Financial Officer

PITTSBURGH and CAMBRIDGE, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, announced today the appointment of Todd P. Branning as Chief Financial Officer (CFO). Mr. Branning has more than 25 years of experience leading corporate finance and accounting, tax, financial planning and analysis, and

Yahoo | January 10, 2022

NeuBase Therapeutics Appoints Dr. Eric J. Ende to Board of Directors

PITTSBURGH and CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, announced today the appointment of Eric J. Ende, M.D., to the Company's Board of Directors. Dr. Ende has nearly 25 years of experience in advising biotechnology and life sciences companies to optimize corporate strategy

Yahoo | January 5, 2022

Analysts Offer Insights on Healthcare Companies: NeuBase Therapeutics (NBSE) and Biohaven Pharmaceutical Holding Co (BHVN)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on NeuBase Therapeutics (NBSE – Research Report) and Biohaven Pharmaceutical Holding Co (BHVN – Research Report) with bullish sentiments. NeuBase Therapeutics (NBSE) H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on NeuBase Therapeutics today and set a price target of $15.00. The company's shares closed last Friday at $2.81, close to its 52-week low of $2.52. According to TipRanks.

Howard Kim on TipRanks | January 3, 2022

NeuBase Therapeutics Reports Business Update and Financial Results for Fiscal Year 2021

Validated ability to Drug the Genome™ to address both rare and common diseases without the limitations of early precision genetic medicine technologies; the Company’s delivery shuttle enables pharmacology across programs in multiple tissues, including in the brain and muscle, after subcutaneous administration Nominated the development candidate for the myotonic dystrophy type 1 (DM1) program with potential for best-in-class features; initiated IND-enabling studies; and expect to submit an IND fi

Yahoo | December 23, 2021

NeuBase Therapeutics, Inc. (NASDAQ:NBSE) Shares Sold by Northern Trust Corp

Northern Trust Corp reduced its stake in NeuBase Therapeutics, Inc. (NASDAQ:NBSE) by 69.9% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 54,926 shares of the companys stock after selling 127,360 shares during the quarter. Northern Trust Corp owned 0.17% of NeuBase Therapeutics worth $263,000 [] The post NeuBase Therapeutics, Inc. (NASDAQ:NBSE) Shares Sold by Northern Trust Corp appeared first on ETF Daily News .

ETF Daily News | December 4, 2021

NeuBase Therapeutics, Inc. (NASDAQ:NBSE) Sees Significant Growth in Short Interest

NeuBase Therapeutics, Inc. (NASDAQ:NBSE) was the target of a significant growth in short interest in October. As of October 15th, there was short interest totalling 593,400 shares, a growth of 18.3% from the September 30th total of 501,500 shares. Based on an average daily volume of 148,700 shares, the days-to-cover ratio is currently 4.0 days. []

Dakota Financial News | November 3, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.493 seconds.